CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 157 enrolled
Drug / intervention
VEGF Trap Eyedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00527423
NCT00527423Phase 2Completed
CompareCT.gov

A Randomized, Single-Masked , Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects With Neovascular Age-related Macular Degeneration

Regeneron Pharmaceuticals·interventional·Posted Sep 10, 2007·Updated Jun 12, 2013

In Brief

A Phase 2 clinical trial evaluating VEGF Trap Eye for Macular Degeneration. Completed, enrolled 157 participants across 33 sites.

Detailed Summary

Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular degeneration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 10, 2007
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 18.8 years ago

Interventions

VEGF Trap Eyedrug

Intravitreal injection